Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.77 |
| ▸ | FLT3 | P36888 | 3/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985733 | 0.93 | AURKA (0.77) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL208679 | 0.88 | AURKA (0.77) | AURKAKCNH2FLT3 | |
| SCHEMBL13985590 | 0.87 | AURKA (0.76) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL209542 | 0.87 | AURKA (0.76) | AURKAKCNH2FLT3 | |
| SCHEMBL29443432 | 0.87 | AURKA (1.00) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL31235734 | 0.87 | AURKA (1.00) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL13985734 | 0.86 | AURKA (0.77) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL4757466 | 0.86 | AURKA (0.64) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL4756080 | 0.83 | AURKA (0.61) | AURKAKCNH2FLT3AURKBAURKC | |
| SCHEMBL208763 | 0.83 | AURKA (0.58) | AURKAKCNH2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| WO-2021262962-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2020-06-18 | — | — | US | disclosed |
| EP-2864328-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | AURKA 293/4885KCNH2 2552/4885FLT3 1075/4885 |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | AURKA 150/4885KCNH2 3093/4885FLT3 1/4885 |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | AURKA 249/4885KCNH2 2466/4885FLT3 1055/4885 |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | FLT3, AURKC, AURKA | AURKA 3/4885KCNH2 2055/4885FLT3 1/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | AURKA 26/4885KCNH2 3642/4885FLT3 672/4885 |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | FLT3, CSF3R, ABL1 | AURKA 150/4885KCNH2 3093/4885FLT3 1/4885 |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | AURKA 249/4885KCNH2 2466/4885FLT3 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.